Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial

We tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.

Citation:
Puvvadi R, Mikkelsen H, McCahon L, Grogan S, Ditcham W, Reid DW, Lamont I, Stick SM, Clements B. Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial. J Cyst Fibros. 2021;20(2):316-23.

Keywords:
Cystic fibrosis; EDTA; Pseudomonas aeruginosa; Tobramycin

Abstract:
We tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.